Diffuse large B-cell non-Hodgkin lymphoma in the very elderly: challenges and solutions.

Feb 2013

Latta S, Cygan PH, Fried W, Nabhan C.

Source

Department of Medicine, Advocate Lutheran General Hospital, Park Ridge, Illinois 60068, USA.

Abstract

Diffuse large B-cell non-Hodgkin lymphoma (DLBCL) is a disease of the elderly, but our current guidelines and treatment paradigms for this disease are based on studies that have mainly enrolled younger patients. Because the number of people living beyond the age of 80 increased by more than 250% between 1960 and 2000, and since it is expected that the population over the age of 75 will triple by 2030, understanding how these elderly patients should be treated is paramount to improving outcomes for this potentially curable lymphoma. In this review, we outline the scope of the problem; we define "the elderly" and identify challenges in assessing this patient population. We also summarize pivotal studies that have been conducted in these elderly patients and suggest an algorithm to aid clinicians in making treatment decisions when faced with DLBCL patients older than 80.

PubMed

Comment in

• The following popper user interface control may not be accessible. Tab to the next button to revert the control to an accessible version.
  Destroy user interface controlWhen can R-CHOP not be used in an elderly patient? [Oncology (Williston Park). 2013]
• 
  
• The following popper user interface control may not be accessible. Tab to the next button to revert the control to an accessible version.
  Destroy user interface controlFffuse large B-cell lymphoma in the very elderly: the case for refining our clinical trials. 
• 
  
• [Oncology (Williston Park). 2013]
• 
  
• The following popper user interface control may not be accessible. Tab to the next button to revert the control to an accessible version.
  Destroy user interface controlDiffuse large B-cell lymphoma in the elderly: leaving our old way(s) behind? [Oncology (Williston Park). 2013]